Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 12, 2013, Pages 1968-1974

  Zhang, Zi Zhen ^a   Liu, Yuan Jie Charles ^b   Yin, Xiao Lu ^b   Zhan, Ping ^b   Gu, Yi ^b   Ni, Xing Zhi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Innovation Center China   (China)

Author keywords

Ataxia telangiectasia mutated; Ataxia telangiectasia mutated Rad3 related; Breast cancer type 1 susceptibility protein; Gastric cancer; Homologous recombination deficiency; Mediator of DNA damage checkpoint protein 1

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; MRE11 PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; FEMALE; FOLLOW UP; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RADICAL RESECTION; STOMACH CARCINOMA; TISSUE MICROARRAY; TUMOR GROWTH;

EID: 84875594162     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i12.1968     Document Type: Article

References (48)

1. van Gent DC, Hoeijmakers JH, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2001; 2: 196-206 [PMID: 11256071 DOI: 10.1038/35056049]
2. Krejci L, Altmannova V, Spirek M, Zhao X. Homologous recombination and its regulation. Nucleic Acids Res 2012; 40: 5795-5818 [PMID: 22467216 DOI: 10.1093/nar/gks270]
3. Tichý A, Vávrová J, Pejchal J, Rezácová M. Ataxia-telangiectasia mutated kinase (ATM) as a central regulator of radiation-induced DNA damage response. Acta Medica (Hradec Kralove) 2010; 53: 13-17 [PMID: 20608227]
4. Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 2003; 421: 961-966 [PMID: 12607005 DOI: 10.1038/nature01446]
5. Stracker TH, Petrini JH. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 2011; 12: 90-103 [PMID: 21252998 DOI: 10.1038/nrm3047]
6. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003; 22: 5784-5791 [PMID: 12947386 DOI: 10.1038/sj.onc.1206678]
7. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-168 [PMID: 12612651 DOI: 10.1038/nrc1011]
8. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009; 361: 1475-1485 [PMID: 19812404 DOI: 10.1056/ NEJMra0804615]
9. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010; 31: 955-960 [PMID: 20351092 DOI: 10.1093/ carcin/bgq064]
10. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010; 31: 961-967 [PMID: 20400477 DOI: 10.1093/carcin/ bgq069]
11. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71 [PMID: 7545954]
12. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12: 68-78 [PMID: 22193408 DOI: 10.1038/ nrc3181]
13. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl) 2006; 84: 16-28 [PMID: 16283147 DOI: 10.1007/ s00109-005-0696-7]
14. Lim AM, Young RJ, Collins M, Fox SB, McArthur GA, Corry J, Peters L, Rischin D, Solomon B. Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncol 2012; 48: 698-702 [PMID: 22410096 DOI: 10.1016/j.oraloncology.20 12.02.014]
15. Guarini A, Marinelli M, Tavolaro S, Bellacchio E, Magliozzi M, Chiaretti S, De Propris MS, Peragine N, Santangelo S, Paoloni F, Nanni M, Del Giudice I, Mauro FR, Torrente I, Foà R. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012; 97: 47-55 [PMID: 21993670 DOI: 10.3324/haematol.2011.049270]
16. Gao Y, Hayes RB, Huang WY, Caporaso NE, Burdette L, Yeager M, Chanock SJ, Berndt SI. DNA repair gene polymorphisms and tobacco smoking in the risk for colorectal adenomas. Carcinogenesis 2011; 32: 882-887 [PMID: 21504893 DOI: 10.1093/carcin/bgr071]
17. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, Muhr D, Wayne TL, Chu G, Davis RW, Wagner TM, Oefner PJ. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003; 63: 3325-3333 [PMID: 12810666]
18. Heikkinen K, Mansikka V, Karppinen SM, Rapakko K, Winqvist R. Mutation analysis of the ATR gene in breast and ovarian cancer families. Breast Cancer Res 2005; 7: R495-R501 [PMID: 15987455 DOI: 10.1186/bcr1037]
19. Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Ouellette G, Pichette R, Plante M, Tavtigian SV, Simard J. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 2006; 6: 230 [PMID: 17010193 DOI: 10.1186/1471-2407-6-230]
20. Monsees GM, Kraft P, Chanock SJ, Hunter DJ, Han J. Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Breast Cancer Res Treat 2011; 125: 207-214 [PMID: 20496165 DOI: 10.1007/s10549-010-0947-3]
21. Patel AN, Goyal S, Wu H, Schiff D, Moran MS, Haffty BG. Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breastconserving surgery and radiation therapy. Breast Cancer Res Treat 2011; 126: 601-607 [PMID: 20521098 DOI: 10.1007/ s10549-010-0960-6]
22. Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, Stucki M, Jackson S, Lukas J, Bartek J. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 2007; 26: 7414-7422 [PMID: 17546051 DOI: 10.1038/ sj.onc.1210553]
23. Yuan C, Bu Y, Wang C, Yi F, Yang Z, Huang X, Cheng L, Liu G, Wang Y, Song F. NFBD1/MDC1 is a protein of oncogenic potential in human cervical cancer. Mol Cell Biochem 2012; 359: 333-346 [PMID: 21853275 DOI: 10.1007/ s11010-011-1027-7]
24. Liu ZK, Zhu SC, Wang YX. Expression of DNA damage checkpoint mediator 1 and p53-binding protein 1 in human esophageal cancer cell lines TE-1, TE-13, and Eca109. Nanfang Yike Daxue Xuebao 2007; 27: 1314-1317 [PMID: 17884766]
25. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008; 2: 296-316 [PMID: 19383352 DOI: 10.1016/molonc.2008.09.007]
26. Dzikiewicz-Krawczyk A. The importance of making ends meet: mutations in genes and altered expression of proteins of the MRN complex and cancer. Mutat Res 2008; 659: 262-273 [PMID: 18606567 DOI: 10.1016/j.mrrev.2008.05.005]
27. Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol Biomarkers Prev 2007; 16: 2024-2032 [PMID: 17932350 DOI: 10.1158/1055-9965.EPI-07-0116]
28. Angèle S, Treilleux I, Brémond A, Tanière P, Hall J. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology 2003; 43: 347-353 [PMID: 14511253]
29. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011; 5: 387-393 [PMID: 21821475 DOI: 10.1016/j.molonc.2011.07.001]
30. Calvert H, Azzariti A. The clinical development of inhibitors of poly(ADP-ribose) polymerase. Ann Oncol 2011; 22 Suppl 1: i53-i59 [PMID: 21285153 DOI: 10.1093/annonc/ mdq667]
31. Irshad S, Ashworth A, Tutt A. Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Rev Anticancer Ther 2011; 11: 1243-1251 [PMID: 21916578 DOI: 10.101586/era.11.52]
32. Leung M, Rosen D, Fields S, Cesano A, Budman DR. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 2011; 17: 854-862 [PMID: 21424107 DOI: 10.2119/molmed.2010.00240]
33. Ebi H, Matsuo K, Sugito N, Suzuki M, Osada H, Tajima K, Ueda R, Takahashi T. Novel NBS1 heterozygous germ line mutation causing MRE11-binding domain loss predisposes to common types of cancer. Cancer Res 2007; 67: 11158-11165 [PMID: 18056440 DOI: 10.1158/0008-5472.CAN-07-1749]
34. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005; 7: 60 [PMID: 16369438]
35. Hu H, Zhang Y, Zou M, Yang S, Liang XQ. Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer. J Cancer Res Clin Oncol 2010; 136: 1407-1414 [PMID: 20127252 DOI: 10.1007/ s00432-010-0795-x]
36. Toller IM, Neelsen KJ, Steger M, Hartung ML, Hottiger MO, Stucki M, Kalali B, Gerhard M, Sartori AA, Lopes M, Müller A. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc Natl Acad Sci USA 2011; 108: 14944-14949 [PMID: 21896770 DOI: 10.1073/ pnas.1100959108]
37. Falchetti M, Saieva C, Lupi R, Masala G, Rizzolo P, Zanna I, Ceccarelli K, Sera F, Mariani-Costantini R, Nesi G, Palli D, Ottini L. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 2008; 39: 925-932 [PMID: 18440592 DOI: 10.1016/j.humpath.2007.10.024]
38. Peshkin BN, Alabek ML, Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis 2010; 32: 25-33 [PMID: 21778580 DOI: 10.3233/BD-2010-0306]
39. Galizia E, Giorgetti G, Piccinini G, Santinelli A, Loretelli C, Bianchi F, Gagliardini D, Carbonari G, Pisa E, Belvederesi L, Bracci R, Ferretti C, Corradini F, Cellerino R. BRCA1 expression in triple negative sporadic breast cancers. Anal Quant Cytol Histol 2010; 32: 24-29 [PMID: 20701084]
40. Semba S, Yokozaki H, Yasui W, Tahara E. Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer. Int J Oncol 1998; 12: 1245-1251 [PMID: 9592181]
41. Chen XR, Zhang WZ, Lin XQ, Wang JW. Genetic instability of BRCA1 gene at locus D17S855 is related to clinicopathological behaviors of gastric cancer from Chinese population. World J Gastroenterol 2006; 12: 4246-4249 [PMID: 16830385]
42. Liu WB, Ao L, Cui ZH, Zhou ZY, Zhou YH, Yuan XY, Xiang YL, Cao J, Liu JY. Molecular analysis of DNA repair gene methylation and protein expression during chemicalinduced rat lung carcinogenesis. Biochem Biophys Res Commun 2011; 408: 595-601 [PMID: 21530494 DOI: 10.1016/ j.bbrc.2011.04.067]
43. Kang B, Guo RF, Tan XH, Zhao M, Tang ZB, Lu YY. Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer. Mutat Res 2008; 638: 17-25 [PMID: 17928013 DOI: 10.1016/j.mrfmmm.2007.08.013]
44. Lewis KA, Bakkum-Gamez J, Loewen R, French AJ, Thibodeau SN, Cliby WA. Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers. Genes Chromosomes Cancer 2007; 46: 1061-1068 [PMID: 17879369 DOI: 10.1002/gcc.20486]
45. Ottini L, Falchetti M, Saieva C, De Marco M, Masala G, Zanna I, Paglierani M, Giannini G, Gulino A, Nesi G, Mariani Costantini R, Palli D. MRE11 expression is impaired in gastric cancer with microsatellite instability. Carcinogenesis 2004; 25: 2337-2343 [PMID: 15319296 DOI: 10.1093/carcin/ bgh257]
46. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012; 18: 1655-1662 [PMID: 22291137 DOI: 10.1158/1078-0432.CCR-11-2890]
47. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392 [PMID: 22452356 DOI: 10.1056/NEJMoa1105535]
48. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol 2011; 12: 852-861 [PMID: 21862407 DOI: 10.1016/S1470-2045(11)70214-5]